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A B S T R A CT  
“Higher the mutation rate higher is the possibility to evolve” and “higher the possibility to evolve 
higher is the possibility of extinction”. Since +ssRNA virus replication is catalyse by their own 
polymerase lacking proofreading activity have high mutation rate; further enhancement of mutation of 
SARS-CoV-2 using nucleotide analogues would be helpful to fight against COVID-19. 
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1 Introduction 
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the aetiology of COVID-19 public-
health emergency (1, 2). SARS-CoV-2 belongs to the subgenus Sarbecovirus of the genus Betacoronavirus; 
nonetheless, genetically distinct from SARS-CoV with similar receptor-binding domain structure with key 
amino acid variation of several residues. Corona virus genome is a single‐stranded positive‐sense RNA 
(+ssRNA) of ~30 kb in length with 5′‐cap structure and 3′‐poly‐A tail (3). As stated elsewhere in numbers 
of reports about hospitalized adult patients with severe COVID-19, use of remdesivir (pro-analogue of 
adenosine triphosphate) appeared to have a favourable effect (4, 5). 
2 High rate of mutation rate during replication of RNA virus 
Replication of RNA viruses is error prone due to lack of proof reading activity of their own replication 
machinery, the RDRP (RNA dependent RNA polymerase), and thus their mutation rates are high. RNA 
viruses yield offspring that differ by 1–2 mutations each from their parent and enhancement of this rate 
would cause for their extinction (6). Inability to maintain their original genome facilitates them to grow in 
novel hosts escaping immune attack up to certain level. In polio- and influenza-virus higher mutation rate 
causes lethal mutagenesis. The exogenous mutagens may cause enough additional mutations, which are 
often deleterious, so that the progeny RNA viruses achieve lower fitness and eventually extinct from the 
environment. Earlier analyses on RNA virus mutation rates suggested that host cell metabolic environment 
normal to the virus put it just under the threshold for lethal mutagenesis; nonetheless, the selection for 
genetic diversity and other consequences of a high mutation rate push RNA viruses to near their 
catastrophic limits (7-10).  
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3 SARS-CoV-2 mutation analyses 
SARS-CoV-2 and other Nidovirales family members including toroviruses and roniviruses are notable 
exceptions as they have an RDRP-independent proofreading activity. This proofreading is thought to be a 
key factor in explaining how these viruses have lower mutation rate and bigger genomes (>26 kb) compared 
to other RNA viruses. A project analysed 220 genomic sequences from the GISAID database derived from 
patients infected by SARS-CoV-2 worldwide from December 2019 to mid-March 2020; keeping SARS-
CoV-2 genome from the GenBank database as reference (11, 12). They executed Genomes alignment 
exploiting Clustal Omega and verified statistical significance using Mann-Whitney and Fisher-Exact tests.  
The project successfully characterized eight novel repetitive mutations of SARS-CoV-2 genome at positions 
1397, 2891, 14408, 17746, 17857, 18060, 23403 and 28881. Mutations in 2891, 3036, 14408, 23403 and 
28881 positions are predominantly observed in Europe, whereas those located at positions 17746, 17857 
and 18060 are exclusively present in North America. They detected a silent mutation in RDRP gene in 
England on February 9th, 2020, and an effective mutation in RDRP differing in amino acid composition 
emerged on February 20th, 2020 in Lombardy, Italy (11). Viruses with RDRP mutation have a median of 
3 point mutations [range: 2-5], otherwise they have a median of 1 mutation [range: 0-3] (p value < 0.001). 
4 Discussion and conclusion 
These findings suggest that the virus is evolving and the contribution of the mutated RDRP to COVID-19 
needs to be exploited. To date, several drugs, including remdesivir targeting RDRP and others targeting the 
main protease enzyme are being employed for SARS-CoV-2 treatment. Some of them have a predicted 
binding moiety in a SARS-CoV-2 RDRP hydrophobic cleft, which is adjacent to the 14408 mutation they 
identified. It is very important to characterize SARS-CoV-2 RDRP mutation in order to understand possible 
drug-resistance strains. In view of this, and the concept “higher the mutation rate higher is the possibility 
to evolve” and “higher the possibility to evolve higher is the possibility of extinction” from Darwin’s theory 
of evolution, and some proven record thereafter in the science of evolution (7, 8), and since there is no 
hope of quick vaccine production (13, 14) and the precise role that nucleotide analogues may play in this 
scenario to induce higher and higher mutation, may be exploited to combat the disease COVID-19. The 
nucleotide analogues, including Azacytidine may be very useful along with remdesivir (see the cartoon). 
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Figure 1. The cartoon depicts that inducing the rate of mutation of SARS-CoV-2 offspring RNAusing nucleotide 
analogues, including azacytidine, ribavirin, GS-5734 etc. (see ref. 10) along with remdesivir (ref. 4,5) may 
expedite the destruction of SARS-CoV-2. The image is the collage of images collected from the Google webs 
without any evil intention. 
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